The Globalization of Indigenous Cultural Festivals: A Global South Residents' Perspectives

The globalization of indigenous cultural festivals has increasingly been affecting the way Intangible Cultural Heritage (ICH) is portrayed and utilized as tourism products due to the deconstruction and reconstruction of cultural meanings and productions. Meanwhile, the role of residents in festivals’ planning, management, and marketing is minimal at best, and non-existent at worst, despite the very essence of these festivals being deeply rooted in their own community culture, beliefs, and shared history. Framed by stakeholder and resource dependence theories and Indigenous Knowledge Systems thinking, this empirical study sought to investigate the interplay between residents and other stakeholders involved in the production and consumption of the Osun Osogbo festival (Nigeria). The findings revealed new theoretical and applied understandings about indigenous cultural festivals planning and management and proposed a stakeholder’s framework to foster a better-informed planning and management process that is economically viable, socially just, and environmentally sustainable in the long term

Pegvisomant in acromegaly: a multicenter real-life study in Argentina

OBJECTIVE: To describe the long term safety and efficacy of pegvisomant (PEGV), and the predictors of treatment response in patients with acromegaly in the real life setting. SUBJECTS AND METHODS: We retrospectively reviewed the clinical, hormonal and radiological data of acromegalic patients treated with PEGV in 17 Argentine centers. RESULTS: Seventy-five patients (age range 22-77, 51 females) with acromegaly have been treated with PEGV for up to 118 months (median 27 months). Before PEGV, 97.3% of patients had been treated with medical therapy, surgery and/or radiotherapy, two patients had no previous treatment. At that time, all patients had an IGF-1 above the upper normal limit (ULN) (mean 2.4 x ULN ± 0.98, range 1.25-7). At diagnosis of acromegaly 84% presented macroadenomas, prior to PEGV only 23,5% of patients remained with tumor remnant > 1 cm, the remaining showed normal or less than 1 cm images. Disease control (IGF-1 ≤ 1.2 x ULN) was achieved in 62.9% of patients with a mean dose of 11.8 mg/day. Thirty-four patients (45%) received PEGV monotherapy, while 41 (55%) received combined therapy with either somatostatin analogues and/or cabergoline. Adverse events related to PEGV were: local injection site reaction in 5.3%, elevated liver enzymes in 9.3%, and tumor size growth in 9.8%. Pre-PEGV IGF-I level was the only predictor of treatment response: 2.1 x ULN vs 2.8 x ULN in controlled and uncontrolled patients respectively (p < 0.001). CONCLUSION: this long term experience indicates PEGV treatment was highly effective and safe in our series of Argentine patients with acromegaly refractory to standard therapies. Arch Endocrinol Metab. 2019;63(4):320-7.FIl: Garcia Basavilbaso, Natalia Ximena. Hospital Carlos G. Durand. Departamento de Endocrinología; Argentina.FIl: Ballarino, Maria Carolina. Hospital Militar Central. Servicio de Endocrinología; Argentina.FIl: Bruera, Darío. Clínica Caraffa. Servicio de Endocrinología; Argentina.FIl: Bruno, Oscar D. Hospital de Clínicas "José de San Martín". Servicio de Endocrinología; Argentina.FIl: Chervin, Alberto B. Hospital Santa Lucía. Servicio de Endocrinología; Argentina.FIl: Danilowicz, Karina. Hospital de Clínicas José de San Martín. Servicio de Endocrinología; Argentina.FIl: Fainstein Day, Patricia. Hospital Italiano. Servicio de Endocrinología; Argentina.FIl: Fidalgo, Silvina Gabriela. Hospital Churruca. Servicio de Endocrinología; Argentina.FIl: Frigeri, Adriana. Hospital Teodoro Alvarez. Servicio de Endocrinología; Argentina.FIl: Glerean, Mariela. Hospital Italiano. Servicio de Endocrinología; Argentina.FIl: Guelman, Rodolfo. Hospital Italiano. Servicio de Endocrinología; Argentina.FIl: Isaac, Gabriel. Hospital Privado de la Comunidad. Servicio de Endocrinología; Argentina.FIl: Knoblovits, Pablo. Hospital Italiano. Servicio de Endocrinología; Argentina.FIl: Librandi, Fabiana. Hospital Rivadavia. Servicio de Endocrinología; Argentina.FIl: López Montes, Monica. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas “José de San Martín”. Servicio de Endocrinología; Argentina.FIl: Mallea-Gil, María Susana. Hospital Militar Central. Servicio de Endocrinología; Argentina.FIl: Manavela, Marcos. Hospital de Clínicas “José de San Martín”. Servicio de Endocrinología; Argentina.FIl: Mereshian, Paula. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas “José de San Martín”. Servicio de Endocrinología; Argentina.FIl: Moncet, Daniel. Hospital Privado de la Comunidad. Servicio de Endocrinología; Argentina.FIl: Katz, Debora Adela. Fleni. Departamento de Neurología. Servicio de Neuroendocrinología; Argentina.FIl: Pignatta, Analia. Hospital Interzonal San Juan Bautista. Servicio de Endocrinología; Argentina.FIl: Rogozinsky, Amelia. Hospital Ramos Mejía. Servicio de Endocrinología; Argentina.FIl: Sago, Laura R. Hospital Italiano de La Plata. Servicio de Endocrinología; Argentina.FIl: Servidio, Marisa. Hospital Teodoro Alvarez. Servicio de Endocrinología; Argentina.FIl: Spezzi, Monica. Instituto Médico Platense. Servicio de Endocrinología; Argentina.FIl: Stalldecker, Graciela. Hospital Pirovano; Argentina.FIl: Tkatch, Julieta. Hospital Carlos G. Durand. Departamento de Endocrinología; Argentina.FIl: Vitale, Nicolas Marcelo. Hospital Santa Lucía. Servicio de Endocrinología; Argentina.FIl: Guitelman, Mirtha. Hospital Carlos G. Durand. Departamento de Endocrinología; Argentina

Measurement Of The Σ̄- Lifetime And Direct Comparison With The Σ+ Lifetime

We have measured the lifetime of the Σ̄- using the Fermilab Proton Center 375 GeV/c charged hyperon beam. We obtained (80.43±0.80±0.14) ps. We also measured the lifetime of the Σ+, obtaining (80.38 ±0.40±0.14) ps, in agreement with the Particle Data Group value. A direct comparison between the two lifetimes from the ratio of the decay curves gives a fractional lifetime difference of Δτ/τ=(-0.06±1.12)%, consistent with equal lifetimes for baryon and antibaryon as required by CPT invariance. ©1999 The American Physical Society.61314Foucher, M., (1992) Phys. Rev. Lett., 68, p. 3004Timm, S., (1995) Phys. Rev. D, 51, p. 4638Dubbs, T., (1994) Phys. Rev. Lett., 72, p. 808Caso, C., (1998) Eur. Phys. J. C, 3, p. 690(1993) GEANT 3.21 CERN Program Library W5103, , CERNKuropatkin, N., private communicationLangland, J.L., (1995) Hyperon and Antihyperon Production in P-Cu Interactions, , Ph.D. thesis, University of IowaMorelos, A., (1993) Phys. Rev. Lett., 71, p. 341

Incorporation of DPP6a and DPP6K Variants in Ternary Kv4 Channel Complex Reconstitutes Properties of A-type K Current in Rat Cerebellar Granule Cells

Dipeptidyl peptidase-like protein 6 (DPP6) proteins co-assemble with Kv4 channel α-subunits and Kv channel-interacting proteins (KChIPs) to form channel protein complexes underlying neuronal somatodendritic A-type potassium current (ISA). DPP6 proteins are expressed as N-terminal variants (DPP6a, DPP6K, DPP6S, DPP6L) that result from alternative mRNA initiation and exhibit overlapping expression patterns. Here, we study the role DPP6 variants play in shaping the functional properties of ISA found in cerebellar granule (CG) cells using quantitative RT-PCR and voltage-clamp recordings of whole-cell currents from reconstituted channel complexes and native ISA channels. Differential expression of DPP6 variants was detected in rat CG cells, with DPP6K (41±3%)>DPP6a (33±3%)>>DPP6S (18±2%)>DPP6L (8±3%). To better understand how DPP6 variants shape native neuronal ISA, we focused on studying interactions between the two dominant variants, DPP6K and DPP6a. Although previous studies did not identify unique functional effects of DPP6K, we find that the unique N-terminus of DPP6K modulates the effects of KChIP proteins, slowing recovery and producing a negative shift in the steady-state inactivation curve. By contrast, DPP6a uses its distinct N-terminus to directly confer rapid N-type inactivation independently of KChIP3a. When DPP6a and DPP6K are co-expressed in ratios similar to those found in CG cells, their distinct effects compete in modulating channel function. The more rapid inactivation from DPP6a dominates during strong depolarization; however, DPP6K produces a negative shift in the steady-state inactivation curve and introduces a slow phase of recovery from inactivation. A direct comparison to the native CG cell ISA shows that these mixed effects are present in the native channels. Our results support the hypothesis that the precise expression and co-assembly of different auxiliary subunit variants are important factors in shaping the ISA functional properties in specific neuronal populations

A standardised model for stool banking for faecal microbiota transplantation : a consensus report from a multidisciplinary UEG working group

Background Faecal microbiota transplantation is an emerging therapeutic option, particularly for the treatment of recurrent Clostridioides difficile infection. Stool banks that organise recruitment and screening of faeces donors are being embedded within the regulatory frameworks described in the European Union Tissue and Cells Directive and the technical guide to the quality and safety of tissue and cells for human application, published by the European Council. Objective Several European and international consensus statements concerning faecal microbiota transplantation have been issued. While these documents provide overall guidance, we aim to provide a detailed description of all processes that relate to the collection, handling and clinical application of human donor stool in this document. Methods Collaborative subgroups of experts on stool banking drafted concepts for all domains pertaining to stool banking. During a working group meeting in the United European Gastroenterology Week 2019 in Barcelona, these concepts were discussed and finalised to be included in our overall guidance document about faecal microbiota transplantation. Results A guidance document for all domains pertaining to stool banking was created. This document includes standard operating manuals for several processes involved with stool banking, such as handling of donor material, storage and donor screening. Conclusion The implementation of faecal microbiota transplantation by stool banks in concordance with our guidance document will enable quality assurance and guarantee the availability of donor faeces preparations for patients.Peer reviewe

A Search for Light Super Symmetric Baryons

We have searched for the production and decay of light super-symmetric baryons produced in 800 GeV/c proton copper interactions in a charged hyperon beam experiment. We observe no evidence for the decays R+(uud \g^~) -> S(uds \g^~) pi+ and X-(ssd \g^~) -> S(uds \g^~) pi- in the predicted parent mass and lifetime ranges of 1700-2500 Mev/c2 and 50-500 ps. Production upper limits for R+ at xF=0.47, Pt=1.4 GeV/c2 and X- at xF=0.48, Pt=0.65 GeV/c2 of less than 10^-3 of all charged secondary particles produced are obtained for all but the highest masses and shortest lifetimes predicted.Comment: 9 pages, uuencoded postscript 4 figures uuencoded, tar-compressed file (submitted to PRL

KV7/KCNQ Channels Are Functionally Expressed in Oligodendrocyte Progenitor Cells

Background: KV7/KCNQ channels are widely expressed in neurons and they have multiple important functions, including control of excitability, spike afterpotentials, adaptation, and theta resonance. Mutations in KCNQ genes have been demonstrated to associate with human neurological pathologies. However, little is known about whether K V7/KCNQ channels are expressed in oligodendrocyte lineage cells (OLCs) and what their functions in OLCs. Methods and Findings: In this study, we characterized KV7/KCNQ channels expression in rat primary cultured OLCs by RT-PCR, immunostaining and electrophysiology. KCNQ2-5 mRNAs existed in all three developmental stages of rat primary cultured OLCs. K V7/KCNQ proteins were also detected in oligodendrocyte progenitor cells (OPCs, early developmental stages of OLCs) of rat primary cultures and cortex slices. Voltage-clamp recording revealed that the IM antagonist XE991 significantly reduced KV7/KCNQ channel current (IK(Q)) in OPCs but not in differentiated oligodendrocytes. In addition, inhibition of K V7/KCNQ channels promoted OPCs motility in vitro. Conclusions: These findings showed that K V7/KCNQ channels were functionally expressed in rat primary cultured OLCs an

Non-pharmacological management of osteoporosis: a consensus of the Belgian Bone Club

This consensus article reviews the various aspects of the non-pharmacological management of osteoporosis, including the effects of nutriments, physical exercise, lifestyle, fall prevention, and hip protectors. Vertebroplasty is also briefly reviewed. Non-pharmacological management of osteoporosis is a broad concept. It must be viewed as an essential part of the prevention of fractures from childhood through adulthood and the old age. The topic also includes surgical procedures for the treatment of peripheral and vertebral fractures and the post-fracture rehabilitation. The present document is the result of a consensus, based on a systematic review and a critical appraisal of the literature. Diets deficient in calcium, proteins or vitamin D impair skeletal integrity. The effect of other nutriments is less clear, although an excessive consumption of sodium, caffeine, or fibres exerts negative effects on calcium balance. The deleterious effects of tobacco, excessive alcohol consumption and a low BMI are well accepted. Physical activity is of primary importance to reach optimal peak bone mass but, if numerous studies have shown the beneficial effects of various types of exercise on bone mass, fracture data as an endpoint are scanty. Fall prevention strategies are especially efficient in the community setting, but less evidence is available about their effectiveness in preventing fall-related injuries and fractures. The efficacy of hip protectors remains controversial. This is also true for vertebroplasty and kyphoplasty. Several randomized controlled studies had reported a short-term advantage of vertebroplasty over medical treatment for pain relief, but these findings have been questioned by recent sham-controlled randomized clinical studies

A standardised model for stool banking for faecal microbiota transplantation: a consensus report from a multidisciplinary UEG working group

Background Faecal microbiota transplantation is an emerging therapeutic option, particularly for the treatment of recurrent Clostridioides difficile infection. Stool banks that organise recruitment and screening of faeces donors are being embedded within the regulatory frameworks described in the European Union Tissue and Cells Directive and the technical guide to the quality and safety of tissue and cells for human application, published by the European Council.Objective Several European and international consensus statements concerning faecal microbiota transplantation have been issued. While these documents provide overall guidance, we aim to provide a detailed description of all processes that relate to the collection, handling and clinical application of human donor stool in this document.Methods Collaborative subgroups of experts on stool banking drafted concepts for all domains pertaining to stool banking. During a working group meeting in the United European Gastroenterology Week 2019 in Barcelona, these concepts were discussed and finalised to be included in our overall guidance document about faecal microbiota transplantation.Results A guidance document for all domains pertaining to stool banking was created. This document includes standard operating manuals for several processes involved with stool banking, such as handling of donor material, storage and donor screening.Conclusion The implementation of faecal microbiota transplantation by stool banks in concordance with our guidance document will enable quality assurance and guarantee the availability of donor faeces preparations for patients.Molecular basis of bacterial pathogenesis, virulence factors and antibiotic resistanc

The effect of testosterone and a nutritional supplement on hospital admissions in under-nourished, older people

Extent: 8p.Background: Weight loss and under-nutrition are relatively common in older people, and are associated with poor outcomes including increased rates of hospital admissions and death. In a pilot study of 49 undernourished older, community dwelling people we found that daily treatment for one year with a combination of testosterone tablets and a nutritional supplement produced a significant reduction in hospitalizations. We propose a larger, multicentre study to explore and hopefully confirm this exciting, potentially important finding (NHMRC project grant number 627178). Methods/Design: One year randomized control trial where subjects are allocated to either oral testosterone undecanoate and high calorie oral nutritional supplement or placebo medication and low calorie oral nutritional supplementation. 200 older community-dwelling, undernourished people [Mini Nutritional Assessment score 7.5% over 3 months)]. Hospital admissions, quality-adjusted life years, functional status, nutritional health, muscle strength, body composition and other variables will be assessed. Discussion: The pilot study showed that combined treatment with an oral testosterone and a supplement drink was well tolerated and safe, and reduced the number of people hospitalised and duration of hospital admissions in undernourished, community dwelling older people. This is an exciting finding, as it identifies a treatment which may be of substantial benefit to many older people in our community. We now propose to conduct a multi-centre study to test these findings in a substantially larger subject group, and to determine the cost effectiveness of this treatment. Trial registration: Australian Clinical Trial Registry: ACTRN 12610000356066Cynthia Piantadosi, Renuka Visvanathan, Vasi Naganathan, Peter Hunter, Ian D. Cameron, Kylie Lange, Jonathan Karnon and Ian M. Chapma